New Stock News | Genuine Biotech Limited's Hong Kong IPO prospectus invalidated

Zhitong
2025.08.18 02:47
portai
I'm PortAI, I can summarize articles.

Genuine Biotech Limited (hereinafter referred to as Genuine Biotech) submitted its Hong Kong stock prospectus on February 18, which became invalid after 6 months on August 18, with CICC as its exclusive sponsor at the time of submission. The prospectus shows that Genuine Biotech is a biotechnology company driven by innovative research and development, focusing on the development, manufacturing, and commercialization of innovative drugs for the treatment of viral infections, tumors, and cardiovascular and cerebrovascular diseases. Its mission is to improve human health through genuine innovation, particularly in the fields of antiviral and anti-tumor therapies, exploring and addressing the issue of drug resistance in existing treatment options. The company aims to find newer and better treatment solutions to address unmet clinical needs. With extensive experience in drug research and development, Genuine Biotech has established a comprehensive R&D platform, including a high-selectivity novel nucleoside broad-spectrum anti-tumor drug development platform, a TOPO1 inhibitor and XDC drug development platform, a drug target discovery and validation platform, and an innovative drug design and optimization platform. These platforms cover the entire drug development process, from early target screening to preclinical research, clinical trials, and subsequent optimization, providing strong technical support and systematic assurance for accelerating the discovery and development of innovative drugs

According to the Zhitong Finance APP, Genuine Biotech Limited (hereinafter referred to as Genuine Biotech) submitted its Hong Kong stock prospectus on February 18, which has expired after 6 months on August 18. CICC was its exclusive sponsor at the time of submission.

The prospectus shows that Genuine Biotech is a biotechnology company driven by innovative research and development, focusing on the development, manufacturing, and commercialization of innovative drugs for the treatment of viral infections, tumors, and cardiovascular and cerebrovascular diseases. Its mission is to improve human health through genuine innovation, particularly in the fields of antiviral and antitumor therapies, exploring and addressing resistance issues in existing treatment options. The company aims to find newer and better treatment solutions to address unmet clinical needs.

With rich experience in drug development, Genuine Biotech has established a comprehensive research and development platform, including a high-selectivity novel nucleoside broad-spectrum antitumor drug development platform, a TOPO1 inhibitor and XDC drug development platform, a drug target discovery and validation platform, and an innovative drug design and optimization platform. These platforms cover the entire drug development process, from early target screening to preclinical research, clinical trials, and subsequent optimization, providing strong technical support and systematic assurance for accelerating the discovery and development of innovative drugs

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.